OncoMatch/Clinical Trials/NCT06672575
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Is NCT06672575 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies Ivonescimab for glioblastoma.
Treatment: Ivonescimab — The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Disease stage
Grade: 4 (WHO CNS 2021)
Diagnosis of Glioblastoma IDH-wildtype, WHO Grade 4 consistent with WHO CNS 2021 criteria. Measurable or evaluable disease per RANO criteria
Prior therapy
Must have received: radiation therapy
patients must have previously been treated with radiation with or without temozolomide
Cannot have received: anti-VEGF therapy
History of prior treatment of GB with anti-VEGF and/or anti-PD-1/PDL-1 agents, including monotherapy with either category or combinations thereof
Cannot have received: anti-PD-1 therapy
History of prior treatment of GB with anti-VEGF and/or anti-PD-1/PDL-1 agents, including monotherapy with either category or combinations thereof
Cannot have received: anti-PD-L1 therapy
History of prior treatment of GB with anti-VEGF and/or anti-PD-1/PDL-1 agents, including monotherapy with either category or combinations thereof
Cannot have received: interstitial brachytherapy
Has received prior interstitial brachytherapy
Cannot have received: interstitial thermal therapy
Has received prior interstitial thermal therapy
Cannot have received: implanted chemotherapy
Has received prior ... implanted chemotherapy
Cannot have received: local injection or convection enhanced delivery
Has received prior ... therapeutics delivered by local injection or convection enhanced deliver
Cannot have received: Gliadel wafer (Gliadel)
Prior treatment with Gliadel ae wafers will be excluded
Lab requirements
Blood counts
ANC 1.5 d7 10^9/L; Platelet count 100 d7 10^9/L; Hemoglobin 9.0 g/dL
Kidney function
Creatinine clearance (CrCL) 50 mL/min or eGFR 50 mL/min; Urine protein < 2+ or 24-hour urine protein quantification < 1.0 g or Urine protein/Creatinine ratio 1mg/mg ( 113.2mg/mmol)
Liver function
Serum total bilirubin (TBIL) 1.5 d7 ULN (or 3 d7 ULN for Gilbert syndrome); AST and ALT 2.5 d7 ULN
Adequate Organ Function, with screening labs performed within 14 days of treatment initiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06672575 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-VEGF therapy, anti-PD-1 therapy, anti-PD-L1 therapy disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages